A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
Latest Information Update: 21 Jan 2025
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Acute heart failure; Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms DAPA ACT HF-TIMI 68
- 17 Jan 2025 Planned End Date changed from 1 Mar 2025 to 1 Jul 2025.
- 17 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 May 2025.
- 19 Sep 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.